Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Cytokine Release Syndrome Management Market, and What Factors Will Drive It?

In recent times, we’ve observed a substantial growth in the market size for cytokine release syndrome management. The expansion is projected to proceed from $22.32 billion in 2024 to $23.76 billion in 2025, boasting a compound annual growth rate (CAGR) of 6.5%. Factors contributing to the historical growth include increased healthcare spending, heightened awareness, evolving lifestyles, significant disposable income, the implementation of personalized medical tactics, and a surge in the use of targeted therapies.

Expectations for the cytokine release syndrome management market indicate robust growth in the coming years, with projections to expand to $30.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this anticipated growth during the forecast period include increased demand for diagnostic tools and treatments, expanded government funding, a surge in demand for efficient therapies, an aging population, as well as initiatives introduced by both public and private organizations. Key trends expected to shape this forecast period involve the use of minimally invasive devices for breast biopsies, the formation of strategic partnerships and collaborations, the provision of antibiotic infusion services at home, the development of innovative drug delivery systems, and the incorporation of electronic health records into infection tracking systems.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Cytokine Release Syndrome Management Market?

The escalating adoption of targeted therapies is projected to spur the expansion of the cytokine release syndrome management market. Targeted therapies refer to drugs or treatments that uniquely obstruct the proliferation and expansion of cancer by tampering with specific molecular targets engaged in tumor development. The accelerated use of these therapies is chiefly due to their ability to meticulously aim at cancer cells, thereby mitigating damage to healthy cells, enhancing the efficacy of treatment, and lessening side effects of conventional therapies. The management of cytokine release syndrome is integral in refining targeted therapies by suppressing severe inflammatory responses, thereby boosting the safety and efficacy of treatments such as CAR-T cell therapy and immune checkpoint inhibitors. For example, in January 2024, the American Society of Gene and Cell Therapy, a US-based gene and cell therapy organization, reported a 10% rise in the number of gene therapies in Phase III clinical trials during the fourth quarter of 2023, indicating the first quarterly increase of this sort since the third quarter of 2022. Consequently, the burgeoning usage of targeted therapies contributes to the growth of the cytokine release syndrome management market.

Which Key Market Segments Comprise the Cytokine Release Syndrome Management Market and Drive Its Revenue Growth?

The cytokine release syndrome managementmarket covered in this report is segmented –

1) By Treatment Type: Monoclonal Antibodies; Corticosteroids; Intravenous Immunoglobulin (IVIG); Targeted Therapy; Supportive Care; Other Treatment Types

2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy; Immune Checkpoint Inhibitors; Hematopoietic Stem Cell Transplantation (HSCT); Autoimmune Diseases; Infections; Other Indications

3) By Route Of Administration: Intravenous (IV); Subcutaneous (SC); Oral; Intramuscular (IM); Intrathecal; Other Routes Of Administration

4) By End Users: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics; Research Institutions; Other End Users

Subsegments:

1) By Monoclonal Antibodies: Tocilizumab; Siltuximab; Infliximab; Rituximab; Other Monoclonal Antibodies

2) By Corticosteroids: Dexamethasone; Prednisone; Methylprednisolone; Hydrocortisone; Other Corticosteroids

3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin; Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin; Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin; Polyvalent Intravenous Immunoglobulin; Other Types of Intravenous Immunoglobulin

4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors; Interleukin-6 (IL-6) Inhibitors; Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors; Bruton’s Tyrosine Kinase (BTK) Inhibitors; Other Targeted Agents

5) By Supportive Care: Antipyretic Medications; Analgesic Medications; Intravenous Fluids And Electrolyte Solutions; Oxygen Therapy; Vasopressor Agents

6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange); Antihistamine Medications; Leukapheresis; Experimental Therapies; Nutritional Support

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24199&type=smp

Which Areas Are Leading Regions in the Cytokine Release Syndrome Management Market Expansion Across the Globe?

North America was the largest region in the cytokine release syndrome management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theCytokine Release Syndrome Management Market Over the Coming Years?

Leading corporations in the cytokine release syndrome management market are intensifying their efforts in clinical trials in order to create advanced treatments, such as host-directed minor molecule medications, designed to alter immune responses and minimize the harsh effects of cytokine storms, without hindering the body’s capacity to combat infections or cancer. A small molecule drug, host-directed, is a compound with a low molecular mass that aims at the host’s immune signaling routes to check uncontrollable cytokine creation, thereby contributing to the management of cytokine release syndrome (CRS) by stopping the over-activation of the immune system. For example, CytoAgents Inc., a biotechnology firm based in the U.S., declared in April 2025, the successful conclusion of the first dosage increment cohort in its Phase 1b/2a clinical trial of CTO1681. This is a host-directed small molecule medication created to prevent and cure CRS in patients receiving CAR T-cell therapy. The trial therapy displayed a positive safety record, with no dose-limiting toxicities or disturbance to the CAR T-cell potency. This trial, which uses a rolling six dose-increase design, is being executed to assess the safety, acceptability, and initial effectiveness of CTO1681, as well as to determine the suggested dose for phase 2.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cytokine-release-syndrome-management-global-market-report

How Is the Cytokine Release Syndrome Management Market Conceptually Defined?

Cytokine release syndrome (CRS) management involves medical strategies to control the excessive immune response caused by an overproduction of cytokines, often seen in conditions such as CAR-T cell therapy or certain infections. It includes the use of medications such as corticosteroids and cytokine inhibitors, supportive care, and sometimes intensive monitoring to prevent severe complications. This management is crucial in reducing the risk of severe organ damage and improving patient outcomes.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24199

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model